Table 2.
Baseline characteristics of the study population.
| Parameters | Trainig set (Rome) | Test set (Udine) | Total |
|---|---|---|---|
| Initial patients | 206 | 67 | 273 |
| No FU | 18 | 7 | 25 |
| Patients included | 188 | 60 | 248 |
| Mean age (years) | 62.84 ± 4.86 | 62.52 ± 5.32 | 62.76 ± 4.98 |
| Sex | |||
| Male | 119 (63.3%) | 36 (60%) | 155 (62.5%) |
| Female | 69 (36.7%) | 24 (40%) | 93 (37.5%) |
| Side | |||
| Left | 77 (41%) | 28 (46.7%) | 105 (42.3%) |
| Right | 111 (59%) | 32 (53.3%) | 143 (57.7%) |
| Tumor site | |||
| Precentral | 63 (33.5%) | 18 (30%) | 81 (32.7%) |
| Postcentral | 50 (26.6%) | 16 (26.7%) | 66 (26.6%) |
| Temporal/insular | 75 (39.8%) | 26 (43.3%) | 101 (40.7%) |
| 5-ALA | |||
| yes | 126 (67%) | 47 (78.3%) | 173 (69.8%) |
| no | 62 (32%) | 13 (21.7%) | 75 (31.2%) |
| Biological features | |||
| MGMT methylation (yes vs no) | 124 vs 64 (66% vs 34%) | 40 vs 20 (66.7% vs 33.3%) | 164 vs 84 (66.1% vs 33.9%) |
| IDH 1/2 mutation (yes vs no) | 8 vs 180 (4.3% vs 95.7%) | 3 vs 57 (5% vs 95%) | 11 vs 237 (4.4% vs 95.6%) |
| Ki-67 (mean) | 24.25 (3-90) | 41,2 (5-75) | 29 (4-80) |
| OS | |||
| Alive (yes vs no) | 53 vs 135 (28.2% vs 71.8%) | 6 vs 54 (10% vs 90%) | 59 vs 189 (23.8% vs 76.2%) |
| Average of FU times (months) | 13.4 (0-35) | 17.1 (0-29) | 14.3 (0-31) |
| PFS | |||
| Class 0 (no 6-months TR) | 109 (58%) | 44 (73.3%) | 153 (61.7%) |
| Class 1 (6-months TR) | 79 (42%) | 16 (26.7%) | 95 (38.3%) |
Characteristics of the study population are described using means ± s.d. (standard deviation) or median and range for continuous variables, number of cases with relative percentages reported in parentheses for categorical variables. Bold values are the corresponding value to Figure 2.
(FU, follow-up; 5-ALA, 5-aminolevulinic acid; MGMT, O-6-Methylguanine-DNA Methyltransferase; IDH, Isocitrate dehydrogenase 1; OS, overall survival; PFS, progression free survival; TR, tumor recurrence).